60 million euros for Tubulis

Tubulis is aiming for clinical evaluation with the help of the financing. The company has also attracted new investors.

Tubulis has closed a Series B financing round of 60 million euros. Andera Partners led the round, Evotec and Fund+ joined. The existing investors Bayern Kapital, Biomedpartners, Coparion, High-Tech Gründerfonds, Occident and Seventure Partners also participated again.

Tubulis specializes in the development of antibody drug conjugates (ADC). These are suitable for the treatment of tumors, for example. However, ADCs can also be toxic to the body. Tubulis is also addressing this problem. Using a linker technology, they increase the specificity and bind new active substances to the antibody.

Tubulis is now aiming to use the funds from the financing round for the clinical evaluation of its proprietary ADC pipeline. The company also plans to launch several programs for solid tumor indications. "This financing round underscores that Tubulis is uniquely positioned to consolidate 20 years of ADC discoveries and translate them into meaningful therapeutic benefits for patients," said Tubulis co-founder and CEO Dominik Schumacher. "We have reached an important inflection point in the development of our platform technologies as well as our pipeline of novel protein-drug conjugates and are now focused on opening new avenues in the treatment of solid tumors and providing patients with safe and effective ADCs."

As part of the financing round, the Board of Directors of Tubulis is also growing: Sofia Ioannidou from Andera Partners, Thomas Hanke from Evotec and Jan Van den Bossche from Fund+ joined the Board. In addition, Valentin Piëch is taking over Michael Wacker's seat for Biomedpartners.